SCHEMBL4307192

SCHEMBL4307192

O=C(Nc1cccc2c1C(=O)N(CC(O)CN1CCN(c3cccc(C(F)(F)F)c3)CC1)C2=O)c1ccc(Cl)s1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.43
LMNA P02545 2/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
HSD17B10 Q99714 1/20 0.43
GAA P10253 2/20 0.42
ALDH1A1 P00352 3/20 0.41
KDM4E B2RXH2 2/20 0.41
KDM4C Q9H3R0 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
IGF1R P08069 1/20 0.41
DRD2 P14416 2/20 0.40
HTR7 P34969 2/20 0.40
HTR1A P08908 1/20 0.40
HTR2A P28223 1/20 0.40
HTR6 P50406 1/20 0.40
ADRB2 P07550 1/20 0.40
ADRB1 P08588 1/20 0.40
ADRB3 P13945 1/20 0.40
ADRA1D P25100 1/20 0.40
ADRA1A P35348 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4307569 0.89 MAPT (0.43) MAPTSMN1; SMN2ALDH1A1DRD2HTR7
SCHEMBL4302294 0.89 MAPT (0.42) MAPTSMN1; SMN2ALDH1A1KDM4EDRD2
SCHEMBL4306503 0.87 F10 (0.42) MAPTLMNAKDM4ETDP1DRD2
SCHEMBL4306493 0.87 F10 (0.43) MAPTLMNASMN1; SMN2DRD2HTR7
SCHEMBL4302265 0.86 F10 (0.44) MAPTSMN1; SMN2HSD17B10ALDH1A1DRD2
SCHEMBL4309841 0.84 RPS6KA2 (0.44) MAPTSMN1; SMN2ALDH1A1KDM4EDRD2
SCHEMBL4306062 0.83 HTR2A (0.42) HSD17B10ALDH1A1KDM4EDRD2HTR7
SCHEMBL4309292 0.83 F10 (0.39) ALDH1A1KDM4EDRD2HTR7HTR1A
SCHEMBL4313299 0.83 HTR1A (0.43) DRD2HTR7HTR1AADRA1DADRA1A
SCHEMBL4310904 0.82 L3MBTL1 (0.45) MAPTLMNASMN1; SMN2HSD17B10GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7482472-B2 Substituted isoindoles and their use BAYER HEALTHCARE AG (DE) 2009-01-27 US disclosed
US-20080039446-A1 Substituted isoindoles and their use BAYER HEALTHCARE AG (DE) 2008-02-14 US disclosed
US-7189738-B2 Substituted isoindoles and their use thereof BAYER HEALTHCARE AG (DE) 2007-03-13 US disclosed
EP-1414817-B1 substituted isoindoles and the use thereof BAYER HEALTHCARE AG (DE) 2005-04-06 EP disclosed
US-20040215019-A1 Substituted isoindoles and the e use thereof BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2004-10-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080039446-A1 Substituted isoindoles and their use F2, F12, TFPI2 MAPT 3401/4885LMNA 956/4885SMN1; SMN2 1980/4885
US-20040215019-A1 Substituted isoindoles and the e use thereof F2, F12, F5 MAPT 4070/4885LMNA 850/4885SMN1; SMN2 2271/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.